Update on HDFN: new information on long-standing controversies

Area of Science:

• Immunology
• Obstetrics
• Neonatology

Background:

• Hemolytic disease of the fetus and newborn (HDFN) arises from maternal IgG antibodies crossing the placenta, causing fetal red blood cell destruction.
• Severe HDFN can lead to hydrops fetalis, heart failure, and intrauterine death.
• While Rh immunoglobulin (RhIG) significantly reduced anti-D HDFN, other RBC antigen alloimmunizations remain a concern.

Purpose of the Study:

• To provide an update on current prevention and treatment strategies for HDFN.
• To highlight recent advancements in managing HDFN caused by various RBC antibodies.
• To discuss ongoing controversies and new insights in HDFN management.

Main Methods:

• Review of current literature on HDFN prevention and treatment.
• Emphasis on noninvasive fetal diagnosis and monitoring techniques.
• Discussion of updated treatment guidelines and management of maternal weak D phenotypes.

Main Results:

• Routine RhIG administration has greatly decreased anti-D HDFN incidence.
• Advances in prenatal care, noninvasive monitoring, and intrauterine transfusion have improved outcomes, even for hydrops fetalis.
• Management of HDFN due to other RBC antigens requires ongoing vigilance and specialized care.

Conclusions:

• HDFN remains a significant concern, necessitating continued research and improved management strategies.
• Noninvasive monitoring and advanced prenatal interventions are crucial for managing HDFN.
• Addressing controversies surrounding weak D phenotypes and D alloimmunization is vital for comprehensive HDFN prevention and treatment.